To investigate a novel suicide gene for nasopharyngeal carcinoma (NPC) therapy, the yCDglyTK gene was constructed by fusing yeast cytosine deaminase (CD) and herpes simplex type 1 thymidine kinase. The expression of the yCDglyTK gene was detected by RT-PCR and Western blotting, and its bioactivity was demonstrated by an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay. An animal study was carried out in which BALB/C nude mice bearing yCDglyTK gene-modified tumors were treated with prodrugs and radiation. Our results revealed that the yCDglyTK gene could be expressed in CNE-2 cells in vitro. In MTT analysis, at the transfection rate of 10%, 66% cells were killed. The synergistic effect of CD and TK showed 91% of yCDglyTK-transfected cells were killed with the treatment of 5-fluorocytosine (5-FC) alone, 60% killed with ganciclovir (GCV) alone, and 75% killed with 5-FC and GCV together. In vivo, the tumor volume in all of the four prodrugs and/or radiation-treated groups were significantly different from that in the PBS-controlled group (Po.01); also yCDglyTK þ prodrug þ radiation group was different from the other three groups (Po.05). Our findings suggested there was a synergistic antitumor effect when combining suicide gene therapy and radiation, and yCDglyTK has potent antitumor efficacy and may be a candidate suicide gene for cancer therapy.
N asopharyngeal carcinoma (NPC) is rare in Western countries but very common in Southern China with an incidence of 10-20/100,000 men/year. 1, 2 Since NPC is highly radiosensitive, it is clinically treated by radiotherapy or combined chemotherapy. However, both therapeutic methods are usually accompanied with many complications, it is very important to find a new treatment approach to lower or eliminate the radio damage.
Gene therapy, especially suicide gene therapy may be a new strategy for NPC treatment. Essentially, suicide gene therapy is a form of intratumor chemotherapy that is currently being evaluated in clinical trials, [3] [4] [5] the main mechanism involved is the intratumor delivery of genes encoding enzymes that convert nontoxic prodrugs into toxic metabolites. Among the most intensively studied suicide genes, two of them most widely used, are bacterial cytosine deaminase (bCD) and herpes simplex type 1 thymidine kinase (HSV-1 TK), which can convert the nontoxic 5-fluorocytosine (5-FC) and ganciclovir (GCV) to the cytotoxic agents 5-fluorouracil (5-FU) and phosphorylated GCV, respectively, the metabolites of which, 5-fluoro-2 0 -deoxyuridine 5 0 -monophosphate (5-FdUMP), 5-fluorouridine 5 0 -triphosphate (5-FUTP) and triphosphorylate GCV, are incorporated into RNA and DNA, resulting in DNA and RNA chain termination and cell death. Thus, the gene transfer of a suicide gene into tumor cells leads to the death of transfected cells after treatment with their prodrugs. It has been reported that these two suicide genes bCD and HSV-1 TK may have synergistic effects in antitumor responses; Rogulski et al 6 constructed a new fusion gene, Escherichia coli CDglyTK, in which the two genes were linked by a polyglycine chain, the fusion gene encoded an 88 kDa protein. Their studies found that the fusion gene could enhance suicide gene activity, and showed radiosensitivity simultaneously. Since the target of the CD gene, 5-FU, is not only a chemotherapeutic agent but also radiosensitive, 7, 8 Ueno et al 9 and other investigators 10 developed a therapeutic strategy for cancer therapy by combining suicide gene therapy and radiotherapy to modulate the expression of the suicide gene in tumors specifically. To further enhance the synergistic effect of radiotherapy and gene therapy, a radio-sensitive promoter, early growth response factor 1 (Egr-1) promoter was applied. 11 The Egr-1 gene encodes an inducible zinc-finger transcription factor, and its expression is modulated during diverse biological processes including cell growth, differentiation and following cellular depolarization. 12, 13 The promoter of the Egr-1 has been described as being activated by ionizing radiation, and the expression of a therapeutic gene controlled by Egr-1 promoter could be regulated by ionizing radiation in temporal, spatial and dose-dependent ways; 14, 15 therefore, this promoter could be used in combination with radiotherapy and suicide gene therapy to elicit the tumor targeted and in the regulation of the expression of a variety of tumor-sensitizing genes. 16, 17 As the prodrug for the E. coli CD suicide gene, 5-FC, is an antifungal agent in clinical application but not an antibacterial drug, Kievit et al 18 and Hamstra et al 19 conducted an experiment to compare the yeast CD (yCD) and E. coli CD in converting 5-FC to 5-FU, and their results confirmed that the yCD was superior to its bacterial counterpart. In this study, we constructed a novel fusion suicide gene, yCD and HSV-1 TK fusion gene linked by a glycine chain (yCDglyTK) encoding a 59 kDa protein. The expression of the fusion gene was controlled by a synthetic CMV-enhanced Egr-1 promoter including CMV enhancer and Egr-1 promoter. In subsequent experiments, the stable CNE-2 colony modified by yCDglyTK was applied to assay the cytotoxicity of yCDglyTK in vitro and in vivo. Here, we have described in detail the fusion gene construction, its suicide activities and antitumorous effect in CNE-2 cells and mice.
Materials and methods

Fusion gene yCDglyTK and expression vector construction
The yCD gene was amplified from the yeast genome with the primers yCD1 (5 0 -CgC,TCg,Agg,CAA,TCA,Tgg,T gA,CAg,ggg,gAA,Tg-3 0 , a Xho I site was added) and CDgly (5 0 -CgT,ggT,ACC,CCC,CTC,ACC,AAT,ATC,TT C-3 0 , a Kpn I site was added). The HSV-1 TK (TK) coding sequence was amplified from pTH2 plasmid (kindly supplied by the Cancer Research Institute, Central South University) using the primers pTKgly (5 0 -ggg, ggT, ACC, ggC, ggg, ggC, ggT, ggA, ggA, ggg, ggT, ATg, gCT, TCg, TAC-3 0 , with a Kpn I site and code for glycine added) and TK1 (5 0 -ACA, AgC, TTT, CAg, TTA, gCC, TCC, CCC, A-3 0 , with a Xho I site). Afterwards, the yCD and TK were ligated together to make a fusion gene yCDglyTK.
To construct a complete expression cassette of yCDglyTK, the CMV enhancer was amplified from pEGFP-N1 (Clontech) with the primers CMV1 (5 0 -AAT, CTA, gAC, CTA, ggA, gTT, CCg, CgT, TAC-3 0 , with a Xba I and Avr II site) and CMV2 (5 0 -CCT, TAT, ATg, gCg, TTT, CCg, ggT, CCg, TTg, ATT, TTg, gTg, C-3 0 ). The Egr-1 promoter was amplified from the mouse genome using Egr-1a (5 0 -gCA, CCA, AAA, TCA, ACg, gAC, CCg, gAA, ACg, CCA, TAT, AAg, g-3 0 ) and Egr-1b (5 0 -ATC, TCg, AgC, CAA, gTT, CTg, CgC, gCT, ggg, ATC, TCT, C-3 0 ). Then, the two fragments were fused to form a CMV-enhanced Egr-1 promoter (CE). We then added CE and BGHpolyA sequences upstream and downstream of yCDglyTK, respectively; a complete expression cassette CEyCDglyTKpolyA was then constructed. Finally, the expression cassette was inserted into a plasmid p11MS with a neomycin gene constructed by our lab to make a recombinant p11MSCEyCDglyTK. The expression cassette is shown in Figure 1 .
Cell culture and transfection CNE-2, an epithelial cell line, established from a poorly differentiated NPC, which proved to be tightly associated with the Epstein-Barr virus (EBV), 20, 21 was obtained from the Animal Center of Zhongshan Medical University and maintained in RPMI 1640 medium (GIBCO) supplemented with 10% heated inactivated fetal bovine serum, 100 IU/ml penicillin, 100 mg/ml streptomycin and 2 mM L-glutamine. Stable yCDglyTK-expressing CNE-2 cells were generated as follows: CNE-2 cells were harvested and added to five 0.4 cm cuvette gap (1 Â 10 7 cells/cup), and the cells were electroporated using 2.0 kV, 25 mF after adding 20 mg plasmid DNA of p11MSCEyCDglyTK. Then, the cells were reseeded into a 200 mm 2 dish, G418 was also added to the media up to a final concentration of 600 mg/ml to allow the formation of single colonies. The single colonies were picked to 12-well plates and assayed by RT-PCR. The total RNA was extracted using TRIzol reagent (GIBCO). The RT-PCR of yCDglyTK was obtained using the AMV reverse transcription Kit (promega) and primers rtCDglyTK1 (5 0 -ggg,AgA,TTA,gAg,ggC,AAA,gTg,T-3 0 ) and rtCDglyT K2 (5 0 -ACg,gCG,TCg,gTC,ACg,gCA,TAA-3 0 ). The human b-actin gene was also amplified as the internal control using the primers b-actin1 (5 0 -Tgg, gTC, AgA, Agg, ACT, CCT, ATg-3 0 ) and b-actin2 (5 0 -CAg, gCA,gCT,CAT,AgC,TCT,TCT-3 0 ). Those CEyCDglyTKexpressing positive CNE-2 colonies were maintained under the selective pressure of G418 (300 mg/ml) and selected for additional studies. The yCDglyTK expressing cassette, composed of synthetic CE promoter, yCDglyTK and BGH polyA, this cassette was digested with AvrII and then the digested product was ligated to NheI-cut p11MS to create p11MSCEyCDglyTK (see ''Materials and methods'').
Western blotting
For Western blotting, CEyCDglyTK-expressing positive CNE-2 cells were harvested, counted and lysed in 2 Â loading buffer (50 mM Tris-HCl, pH 7.5; 150 mM NaCl, 5 mM EDTA, 1 mM DTT, 1% Triton X-100) and incubated for 5 minutes at 991C. Cell extracts were applied to a 10% SDS-PAGE and transferred onto PVDF membrane using standard procedures. Blots were probed with a mouse monoclonal antibody to human HSV-1 TK (QED) and a rabbit anti-mouse IgG antibody (Sigma) served as a secondary antibody. Hybridization was visualized using the ECL chemiluminescence detection system (Amersham).
MTT Assay
The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay, an index of cell viability and cell growth, was based on the ability of viable cells to reduce MTT from a yellow water-soluble dye to a dark blue insoluble formazan product. 22 CEyCDglyTK-expressing CNE-2 clone and wild-type CNE-2 cells were seeded in 96-well plates (Falcon 3072, Becton-Dickinson, Lincoln Park, NJ) at 3000 cells per well and incubated at 371C for 24 hours. The cells were then treated with 5-FC or/and GCV at eight different concentrations (5-FC: 0, 20, 50, 100, 200, 400, 800, 1200 mg/ml; GCV: 0, 2, 4, 8, 10, 20, 40, 80 mg/ml), and returned to the incubator for 5 days. MTT dye (0.5 mg/ml) was added to each well for the last 4 hours of treatment. The reaction was stopped with the addition of DMSO (Promega, Madison, WI), and the optical density was determined at 490 nm on a multiwell plate reader (Bio-Rad model 3550, Bio-Rad, Mississauga, Canada). Background absorbance of the medium in the absence of cells was subtracted. All samples were assayed in duplicate, and the mean for each experiment was calculated. Results were expressed as a percentage of control, which was considered as 100%.
Determining the ''by-stander effect'' of yCDglyTK/5-FC system
To determine the ''by-stander effect'' of yCDglyTK/5-FC system, CEyCDglyTK expressed and unmodified wildtype CNE-2 cells were mixed by the proportions of 0, 5, 10, 20, 50, 80, 90 and 100%, and then seeded into a 96-well plates (3000 cells/well). After 7 days of treatment with 5-FC (200 mg/ml), the cell viability of these mixed cells were assayed by MTT method (procedure see to above).
In vivo experiments
Animal experiments were approved by the Animal Test Center of China. To evaluate the therapeutic efficacy of CEyCDglyTK, 5-FC and radiation-combined therapy to suppress NPC growth in animal model, we employed stable CEyCDglyTK-expressing CNE-2 cells and nonmodified CNE-2 cells to inoculate BALB/C nude mice (aged of 4-6 weeks, about 20 g, female, purchased from Animal Center of Shanghai, China). All mice (n ¼ 40) 60 Co g-radiation was given exclusively to the tumor location of mice three times with a dose of 3 Gy. The time interval between 5-FC and radiation in the combined treatment was 3 hours. Tumors were measured for 3 days, using calipers, by a blinded observer. When the tumor volumes of mice in yCDglyTK-expressing tumor þ PBS group reached to 3000 mm 3 or the tumors on large fraction of mice in five groups began to exhibit extensively, the study was stopped.
Statistical analysis
Statistical analysis was performed by SPSS 10.0 for windows (one-way ANOVA). Po.05 was considered to be statistically significant.
Results
Expression of yCDglyTK in NPC cells
The fusion gene yCDglyTK was amplified from mRNA of CNE-2 cells transfected by the vector p11MsCEyCD-glyTK, and an expressed protein of 59 kDa was also detected in the yCDglyTK-expressing CNE-2 cell extracts (Fig 2) .
yCDglyTK/5-FC system has powerful ''by-stander effect'' As seen in Figure 3 , the mean cell death percentage (100%Àcell viability) were significantly different among 
eight proportions (Po.01). At the 5% rate of CEyCDglyTK-expressing cells, 43.60% cells were killed, at the 10% rates, 66% cell killed, at the 20% rate, 82.5% cells killed. These results indicated that the yCDglyTK/5-FC system has powerful ''by-stander effect'', which can kill the neighbor untransferred cells in large quantities.
Prodrug concentrations and cytotoxicity of yCDglyTK/prodrug systems
As seen in Figure 4 , the yCDglyTK-positive CNE-2 cells and wild-type CNE-2 cells were treated with eight concentrations of 5-FC or/and GCV. On the treatment of 200 mg/ml 5-FC, the mean cell survivability of yCDglyTK-positive CNE-2 cells was 18% and that of wild-type CNE-2 cells was 84%; on the treatment of 10 mg/ml GCV, the cell viability of the former was 54% and the latter was 97%, at the 200 mg/ml 5-FC plus 10 mg/ ml GCV, the former was 28% while the latter was 98% and at the level of 1200 mg/ml 5-FC, yCDglyTK-positive CNE-2 cells reached to 15% and the wild-type CNE-2 cells had 82% cell viability. From the information obtained in Figure 4 , we may draw two conclusions; firstly, the cell survival probability of wild-type CNE-2 cells in the presence of 5-FC is under the level of 100%, indicating that the 5-FC might have little toxicity on CNE-2 cells; and secondly, the significant difference between the two cell lines on cell viability index indicates that the potent cytotoxicity of yCDglyTK for CNE-2 cell at a concentration of 200 mg/ml 5-FC is clearly effective.
Cytotoxicity in vivo
To investigate the antitumorous effect of yCDglyTK fusion gene in combination with radiation for NPC tumor in nude mice, CEyCDglyTK-expressing and normal CNE-2 xenografts were made on 40 nude mice that were assorted in five experimental groups. After giving different treatments of prodrugs and radiation, potent growth inhibition on the explanted tumors were observed in CNE-2 þ 5-FC þ radiation, yCDglyTK þ 5-FC, yCDglyTK þ radiation, yCDglyTK þ 5-FC þ radiation groups as compared to that of nude tumors in yCDglyTK þ PBS group (Po.01), and a significant difference (Po.05) between yCDglyTK þ 5-FC þ GCV þ radiation group and other three groups (Fig 5) was also shown. These data indicated that the tumor regression could be accomplished by suicide gene therapy alone, radiation alone or the combined therapy of both. It also revealed that the combination of suicide gene therapy and radiotherapy has synergic antitumorous response for the NPC.
Discussion
HSV-1 TK and CD are two of the most intensely studied suicide genes, and two fusion suicide genes yCD/UPRT (uracil phosphoribosyltransferase) and E. coli CDglyTK were considered as the most effective in conversion nontoxic prodrugs into cytotoxic metabolites. [23] [24] [25] In our study, we utilized a novel fusion gene yCDglyTK under the control of a synthetic promoter CE, the CMV enhancer increasing the regulation force of Egr-1 promoter proven by our previous study, 26 to kill NPC cells by combining with radiation. The suicide vector p11MsCEyCDglyTK was transferred onto CNE-2 cells A novel fusion gene yCDglyTK for cancer therapy K Xia et al and this suicide gene was successfully expressed at both mRNA and protein levels. The potent cytotoxicity of the yCDglyTK gene in the presence of prodrugs was confirmed by the results of the MTT assay, and the yCDglyTK/5-FC system was superior to the yCDglyTK/ GCV system which is consistent with the reports of others. 27, 28 Since the yCD and HSV-1 TK may have a synergistic effect to enhance the antitumorous response, we compared the cytotoxicity of this fusion gene in the presence of 5-FC alone, GCV alone and combined 5-FC/GCV together. The results of MTT analysis showed that the cell viability of yCDglyTK-expressing cells was 18% in the presence of 200 mg/ml 5-FC, 28% at 5-FC (200 mg/ ml) þ GCV (10 mg/ml) and 54% at GCV alone (Fig 4) . The results indicated that both yCDglyTK/5-FC and yCDglyTK/GCV were active, and the cytotoxicity of yCDglyTK/5-FC sysytem is higher than that of yCDglyTK/GCV for NPC cells, but the combined system did not show the optimal effect among the three systems that were of our expectations, but superior to yCDglyTK/ GCV system and inferior to the yCDglyTK/5-FC system, which differed from other reports. 6, 29, 30 These observations could be explained in two ways. First, the yCD and TK may have reciprocal interference in our yCDglyTK/5- 0 -diphosphate (5-FUDP) and 5-FUTP, thereby reducing the cytotoxicity of the CD/5-FC system, or the CD-mediated deamination of TK-activated GCV or its toxic derivative would diminish the cytotoxicity of the TK/GCV system. From the observations that yCDglyTK/5-FC was superior to the yCDglyTK/5-FC þ GCV, we were inclined to believe the former, that is, the TK-mediated phosphorylation of 5-FUMP or 5-FdUMP would reduce the amounts of 5-FUTP and 5-FdUMP, thus reducing the cytotoxicity of CD/5-FC system. The second possibility is that as the cytotoxicity of yCDglyTK/5-FC was very potent as described above, the activities of yCD or TK in yCDglyTK gene may be greater than that of yCD or TK alone. Erbs et al 32 constructed a yCD/UPRT fusion gene, and their studies showed that the UPRT activity of yCD/UPRT was equivalent to that encoded by yUPRT, but its CD activity was 100-fold higher than the one encoded by yCD. To resolve these issues, it is necessary to compare the cytotoxicity of four suicide strategies including yCD/5-FC, yCDglyTK/5-FC, yCDglyTK/ GCV and TK/GCV systems. Although our study was repeated three times and manipulated by different researchers, the results show higher consistency. The influence of locations and copy number of suicide genes inserted into the chromosomes of the yCDglyTK-expressing positive colonies was difficult to estimate in this study. Therefore, the findings in the present study should serve as a cautionary note and the exact mechanism should be explored in further studies.
To extend these in vitro findings to an animal model, we investigated the antitumorous effect of p11MS-medicated yCDglyTK fusion gene in combination with the radiation in nude mice. To avoid the mutual interference of double genes, only the 5-FC was given to the mice. The results of this animal study showed that a frank regression of tumor volumes can be achieved by suicide gene therapy alone, radiotherapy alone and by the combination of suicide gene and radiation, which revealed that the yCDglyTK/5-FC systems are active in vivo and the combination of suicide gene therapy and radiotherapy has a synergistic effect in antitumor activity in the radio-gene therapy of NPC xenografts mice model.
For NPC cells, which are highly radiosensitive, historically the main modalities are radiotherapy or combination with chemotherapy. However, high doses of radiation render by-stander normal tissue damage and induce resistance to radiation in the NPC cells that may result in incomplete cure and recurrence of tumors. Thus, the methods to kill effectively the tumors with as low as possible dose of radiation were required to search for a clinical benefit. In this study, we investigated the effect of Figure 5 Growth curves of yCDglyTK-expressing CNE-2 tumors and wild-type CNE-2 tumors. 5-FC (500 mg/kg) was given daily for 9-21 days of implanting tumor cells. Radiations were given exclusively to the tumor location of mice at the 10th, 12th, and 14th day with a dose of 3 Gy, respectively. &: wild-type CNE-2 tumors were treated with radiation and 5-FC; ': yCDglyTK-expressing tumors were treated with PBS; J: yCDglyTK-expressing tumors were treated with 5-FC; K: yCDglyTK-expressing tumors were treated with radiation; E: yCDglyTK-expressing tumors were treated with 5-FC and radiation. On the 36th day, the tumors on a large fraction of mice in five groups begin to show necrosis prevalently, the study was stopped. After given the prodrugs and radiations to the studied mice as described above, potent growth inhibition on the explanted tumors were observed in CNE-2 þ 5-FC þ radiation, yCDglyTK þ 5-FC, yCDglyTK þ radiation, yCDglyTK þ 5-FC þ radiation groups as compared to that of nude tumors in yCDglyTK þ PBS groups (Po.01), and a significant difference (Po.05) was also shown between yCDglyTK þ 5-FC þ GCV þ radiation group and the other three groups. The error bars represent the standard error of the means (n ¼ 8).
A novel fusion gene yCDglyTK for cancer therapy K Xia et al combination of a new fusion suicide gene yCDglyTK with radiation for NPC therapy in vitro and in vivo, but for further clinical practice, some issues must be resolved. Firstly, we need the appropriate dose of radiation to trigger the expression of suicide gene controlled by Egr-1 promoter and not solicitation of complications for the radiation recipient. In our in vivo study, although none of nude mice represent complications (weight loss and death), tumors recurred soon after stopping injection of prodrugs, which may indicate that the combined treatments need to be regulated in order to cater for optimal radio-gene therapy of cancers in clinical trials. We still need to explore the optimal strategy of prodrug and radiation administration such as hyperfractionated or accelerated hyperfractionated radiation. Secondly, our nonviral vector has low transduction efficiency to enter into the targeted cells when delivering suicide genes by the method of intratumorous injection, which is the main obstacle for additional clinical practice. At present, the most frequently used systems for transfecting foreign genes into various types of cells or tissues are adenovirus vector, retrovirus vector and liposome method. However, the retrovirus vector is expressed at low levels in vitro, liposome has some toxicity to mammalian cells, and the adenovirus vector cause unfavorable immune reaction of the host. In our laboratory, a silica nanoparticle was constructed that has shown high efficiency of DNA transferring into cells and safety, 33 and the study of nanoparticle-delivering suicide gene through intratumorous injection is well underway.
Although radiotherapy is the main treatment for NPC for a long term, the combined therapy with a diminished dose of radiation plus tumor-targeting killer, a suicide gene, may provide a more effective and safer alternative for the treatment of NPC, and in this present paper the yCDglyTK fusion gene showed potent antitumor efficacy such that it may be a candidate suicide gene for cancer therapy. 0 -deoxyuridine 5 0 -triphosphate; Egr-1, early growth response factor 1; DPD, dihydropyrimidine dehydrogenase; UPRT, uracil phosphoribosyltransferase.
